▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2164 by analyst upside · 2026-09-26
STAA
STAAR Surgical Company
Healthcare · Market Cap $1B · P/E 256.4x
ANALYST PRICE TARGET
+33.6%
implied upside to consensus target
Current Price $20.51
Consensus Target $27.4
Bull Target $37.0
Bear Target $19.0
Analysts Covering 10
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
2
Hold
7
Sell
1
52-Week Low $15.59
52-Week High $35.87
YTD Return -13.1%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) 256.4x
Forward P/E 20.0x
EPS (TTM) $0.08
PEG Ratio 0.76
Dividend Yield N/A
Revenue (TTM) $340M
Profit Margin 1.1%
52-WEEK RANGE
52-Week Low $15.59
52-Week High $35.87
Current Price $20.51
Bear Target $19.0
Bull Target $37.0
● Now $20.51 ● Target $27.4
TRADING DATA
Avg Volume 999K
YTD Return -13.1%
Analyst Count 10
Consensus Hold
Upside to Target +33.6%
Last Updated 2026-09-26

ANALYST SUMMARY

STAAR Surgical Company (STAA) is currently trading at $20.51 with a Wall Street consensus price target of $27.4, implying potential upside of 33.6% over the next 12 months. 10 analysts currently cover STAA, with a consensus rating of Hold - 20% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $37.0, while the most cautious has a target of $19.0.

STAA operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 13.1% year-to-date and is currently trading near the lower end of its 52-week range of $15.59 – $35.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RGEN -0.1%
Repligen Corporation
$11B · P/E 263.4x · Buy
CORT +21.4%
Corcept Therapeutics Incorporated
$13B · P/E 258.0x · Buy
ICUI +17.2%
ICU Medical, Inc.
$4B · P/E 137.5x · Buy
ICLR +7.5%
ICON Public Limited Company
$13B · P/E 269.3x · Buy
MDXG +58.5%
MiMedx Group, Inc.
$682M · P/E 116.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for STAA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Jefferies - Reiterated
Buy → Buy 2026-09-22 50% win rate (6 calls)
Stifel - Reiterated
Hold → Hold 2026-08-17 Building track record
UBS - Reiterated
Sell → Sell 2026-08-13 33% win rate (6 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-08-13 Building track record
Jefferies - Reiterated
Buy → Buy 2026-08-13 50% win rate (6 calls)
Wedbush reit
Outperform → Outperform 2026-08-04 Building track record
UBS ● Initiated
Sell 2026-07-28 33% win rate (6 calls)
Wedbush reit
Outperform → Outperform 2026-07-22 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
32
out of 100
Coverage depth
18/30
Consensus clarity
12/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →